Daniel J Pratt

US Patent:

7923032, Apr 12, 2011

Filed:

Nov 26, 2003

Appl. No.:

10/723626

Inventors:

Daniel Pratt - Amesbury MA, US
Samuel S. MacAusland - Wellesley MA, US
Keith Baker - Danvers MA, US

Assignee:

Seacoast Neuroscience, Inc. - Amesbury MA

International Classification:

A61K 9/14
A61K 9/00
A61K 9/10
A61K 31/13
A61K 31/131
A61K 31/14
A61K 31/56
A61K 31/59

US Classification:

424489, 514167, 514169, 514579, 514659, 514728, 514774, 514776, 514781, 514947, 514951

Abstract:

The invention provides compositions and methods for treating a subject who has suffered from a central nervous system disorder. More particularly, the invention provides sustained polymeric drug delivery systems having a polymer particle, a therapeutic agent, and a buoyancy agent for direct delivery of therapeutic agents into the central nervous system.

US Patent:

8367116, Feb 5, 2013

Filed:

Mar 18, 2011

Appl. No.:

13/051331

Inventors:

Daniel Pratt - Amesbury MA, US
Samuel S. Macausland - Wellesley MA, US
Keith Baker - Danvers MA, US

Assignee:

Seacoast Neuroscience, Inc. - Amesbury MA

International Classification:

A61K 9/00
A61K 9/10
A61K 9/14
A61K 31/13
A61K 31/131
A61K 31/14
A61K 31/56
A61K 31/59

US Classification:

424489, 514167, 514169, 514579, 514659, 514728, 514774, 514776, 514781, 514947, 514951

Abstract:

The invention provides compositions and methods for treating a subject who has suffered from a central nervous system disorder. More particularly, the invention provides sustained polymeric drug delivery systems having a polymer particle, a therapeutic agent, and a buoyancy agent for direct delivery of therapeutic agents into the central nervous system.

US Patent:

61239569, Sep 26, 2000

Filed:

Jul 9, 1998

Appl. No.:

9/112708

Inventors:

Keith Baker - Danvers MA
Mark Kieras - Newburyport MA
Martin Redmon - Marlborough MA
Daniel Pratt - Amesbury MA

International Classification:

A61F 202
A61F 950

US Classification:

424426

Abstract:

A method for universally distributing a therapeutic agent, in an encapsulated form, to the brain of a subject using intrathecal administration, excluding the lumbar region, is described. Methods for treating stroke and/or Traumatic Brain Injury (TBI) are also described. The methods involve intrathecal administration into the cerebrospinal fluid of a subject, of a therapeutic agent in an encapsulated form. Pharmaceutical compositions intended for the amelioration of stroke and/or Traumatic Brain Injury (TBI) are also described. The pharmaceutical compositions comprise a therapeutic agent encapsulated in a pharmaceutically acceptable polymer, suitable for injection into the cerebrospinal fluid of a subject suffering from stroke and/or Traumatic Brain Injury (TBI).